en · de · es · fr · pt
semax-notes.peptides4800.com › Faq › Background And Development — Common Mistakes

Background And Development — Common Mistakes

By Editorial Desk · published 2026-02-28 · last reviewed 2026-03-17 · Faq

The short version of Semax fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Semax at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideAnalog of an ACTH fragment
Amino acid lengthSeven residuesMet-Glu-His-Phe-Pro-Gly-Pro
OriginMoscow, 1980sInstitute of Molecular Genetics
Approved regionsRussia and some neighboring statesNot cleared in Western markets
Common trade namesMultiple national brandsSold as a nasal formulation

Semax Peptide Background and Identity

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Related pages on this site

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Further detail

=== Research === In 2013, Rocky De Nys and his team at JCU along with CSIRO performed in vitro tests on 30 tropical macroalgae species using an artificial cow stomach. Dried seaweed biomass was mixed in with low quality roughage and combined with rumen fluid. Temperature and pH were then maintained to accurately simulate the fermentation process that occurs within ruminant stomachs during digestion. The total volume and concentrations of produced gases were measured for each sample at 12-hour intervals over a 72-hour period. All seaweed species were shown to reduce methane emissions in some capacity with a 50% average reduction. However this required dosages as much as 20% of dietary intake. This was problematic as the high concentrations required would most likely cause digestion issues for livestock by reducing the volume of volatile fatty acids. Asparagopsis taxiformis proved the most effective with a measured methane reduction of 98.9%. Dictyota was the second most effective seaweed with a measured methane reduction of 92%. The results of this experiment provided sufficient evidence for CSIRO to select Asparagopsis as the main ingredient in livestock feed. In 2014, a patent on a method for reducing total gas production and/or methane production in ruminants (such as sheep and cattle) was registered by CSIRO, MLA and JCU. De Nys and Kinley expanded upon the experiment in 2015 with the goal of finding an ideal dosage of Asparagopsis. The aim was to maximise methane reduction without compromising enteric health.

Continuous glucose monitors (CGMs) are wearable sensors which extrapolate an estimate of the glucose concentration in a patient's blood based on the level of glucose present in the subcutaneous interstitial fluid. A thin, biocompatible sensor wire coated with a glucose-reactive enzyme is inserted into the skin, allowing the system to read the voltage generated, and based on it, estimate blood glucose. The biggest advantage of a CGM over a traditional fingerstick blood glucose meter is that the CGM can take a new reading as often as every 60 seconds (although most only take a reading every 5 minutes), allowing for a sampling frequency that is able to provide not just a current blood sugar level, but a record of past measurements; allowing computer systems to project past short-term trends into the future, showing patients where their blood sugar levels are likely headed.

During the 1950s and 1960s, CSL produced semisynthetic penicillin as well. Penicillin was also produced by F.H. Faulding in South Australia, Abbott Laboratories in New South Wales and Glaxo in Victoria. By the 1970s there was a worldwide glut of penicillin. Glaxo ceased production in 1975 followed by CSL in 1980.

Sources: en.wikipedia.org

Background from the literature

=== Neonate === To ensure the safety of blood transfusion to pediatric patients, hospitals are taking additional precautions to avoid infection and prefer to use pediatric blood units that are guaranteed "safe" from Cytomegalovirus. Some guidelines have recommended the provision of CMV-negative blood components and not simply leukoreduced components for newborns or low birthweight infants in whom the immune system is not fully developed, but practice varies. These requirements place additional restrictions on blood donors who can donate for neonatal use, which may be impractical given the rarity of CMV seronegative donors and the preference for fresh units. Neonatal transfusions typically fall into one of two categories:

centriole A cylindrical organelle composed of microtubules, present only in certain eukaryotes. A pair of centrioles migrate to and define the two opposite poles of a dividing cell where, as part of a centrosome, they initiate the growth of the spindle apparatus.

== 21st century == The Progressive Alliance is a political international organisation founded on 22 May 2013 by left-wing political parties, the majority of which are current or former members of the Socialist International. The organisation states that its aim is becoming the global network of "the progressive, democratic, social-democratic, socialist and labour movement." On 30 November 2018, The Sanders Institute and the Democracy in Europe Movement 2025 founded the Progressive International, an international political organisation which unites democratic socialists with labour unionists, progressives and social democrats.

Sources: en.wikipedia.org

Further detail

=== Drug-drug interactions === Drug−drug interactions (DDI) are one of the primary causes of adverse drug reactions which can result in serious health issues. In 1981, Aarons said that because of the practice at the time of multiple drug therapy, there was a good chance of drug-drug interaction. He reviewed the literature around pharmacokinetic interactions when there is a change of the disposition of the interacting drugs, in particular, the mechanisms that cause these changes. He noted that in drug-drug interactions both drugs are often affected, and it is necessary to develop "a model that describes the disposition of all interacting species." In 2011 Aaron was part of a team that critiqued the then two-fold method of assessing drug-drug interaction and proposed that there would be less bias if predictions were made using a wider range of data collected and the allowance of variability was included in the process. A research programme in 2017 that Aarons was involved in explored the mechanistic prediction of the oral bioavailability differences observed between the original formulation of a drug and that on its release. The study predicted that bioavailability of the original drug was due to reduced deactivation by an enzyme CYP3A4 in the intestine This was proven in the study, which concluded that "this work highlights the importance that formulations can have [when there are] clinically-relevant DDI involving CYP3A substrates...[and that]...

=== Selected articles === Vom Saal, F. S., Akingbemi, B. T., Belcher, S. M., Birnbaum, L. S., Crain, D. A., Eriksen, M., ... & Zoeller, R. T. (2007). Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reproductive Toxicology, 24(2), 131–138. LeBlanc G.A. (2007). Crustacean endocrine toxicology: a review. Ecotoxicology, 16, 61–81. Camp A. A., Yun J., Chambers S. A., Maher H. H., LeBlanc G. A. (2020). Involvement of glutamate and serotonin transmitter systems in male sex determination in Daphnia pulex. Journal of Insect Physiology. 121: doi.org/10.1016/j.jinsphys.2020.104015. Xu, X., Zhou, G., Lei, K., LeBlanc, G. A., & An, L. (2020). Phthalate esters and their potential risk in PET bottled water stored under common conditions. International Journal of Environmental Research and Public Health, 17(1), 141. Ford, A. T., & LeBlanc, G. A. (2020). Endocrine disruption in invertebrates: A survey of research progress. Environmental Science & Technology, 54(21), 13365–13369. Morthorst J.E, Holbech H., De Croze N., Mattiessen P., & LeBlanc G.A. (2022). Thyroid-like hormone signaling in invertebrates and its potential role in initial screening of thyroid hormone system disrupting chemicals. Integrative Environmental Assessment & Management. 18:62-82.

Loss of perivascular collagen occurs; it is thought that this is due to the degradative enzymes released by extravasating leukocytes, such that the collagen and other connective tissue fibers surrounding blood vessels in the area dissolve. When this occurs the gums will appear bright red and either bulbous or rounded, from all the excess fluid building up in the infected area. The initial lesion appears within two to four days of gingival tissue being subjected to plaque accumulation. When not generated through clinical experimentation, the initial lesion may not appear at all, and instead, a detectable infiltrate similar to that of the early lesion, explained below, appears.

In summary, acetyl-CoA controls its own mitochondrial consumption via mtFAS and acylated ACP, enhancing oxidative capacity in times of substrate excess and downregulating electron transport chain activity under substrate-limited conditions to prevent reactive oxygen species (ROS) generation. Ketone body formation and utilization: Two acetyl-CoA molecules condense to form acetoacetyl-CoA, which gives rise to the formation of acetoacetate and β-hydroxybutyrate. Acetoacetate, β-hydroxybutyrate, and their spontaneous breakdown product acetone are frequently, but confusingly, known as ketone bodies (as they are not "bodies" at all, but water-soluble chemical substances). The ketone bodies are released by the liver into the blood. All cells with mitochondria can take ketone bodies up from the blood and reconvert them into acetyl-CoA, which can then be used as fuel in their citric acid cycles, as no other tissue can divert its oxaloacetate into the gluconeogenic pathway in the way that the liver does. Unlike free fatty acids, ketone bodies can cross the blood–brain barrier and are therefore available as fuel for the cells of the central nervous system, acting as a substitute for glucose, on which these cells normally survive. The occurrence of high levels of ketone bodies in the blood during starvation, a low-carbohydrate diet, prolonged heavy exercise, and uncontrolled type-1 diabetes mellitus is known as ketosis, and in its extreme form in out-of-control type-1 diabetes mellitus, as ketoacidosis.

Sources: en.wikipedia.org

Frequently asked questions

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Is Semax an approved medication anywhere?

It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.

What is the relationship to ACTH?

Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.

What is Semax chemically?

It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.

Network